Non-alcoholic fatty liver disease: a heterogeneous phenotype. Pleiotropic effects of ursodeoxycholic acid
https://doi.org/10.51793/OS.2023.26.8.003
Abstract
Background. Non-alcoholic fatty liver disease occupies a leading position among the causes of diffuse liver diseases, both in Russia and in the world, while there is a steady upward trend in the incidence, especially in the cohort of patients with metabolic risk factors. In Russia, over the past 7 years, the number of patients suffering from non-alcoholic fatty liver disease has increased by 10%. However, the prevalence of non-alcoholic fatty liver disease appears to be much higher because the first-line imaging test, ultrasonography, has limited sensitivity. Morphological criteria of the disease is the presence of steatosis in more than 5% of hepatocytes. The disease is associated with disorders of carbohydrate metabolism – insulin resistance and is more of a general term that includes the main forms of the disease: non-alcoholic fatty hepatosis, steatohepatitis, the outcomes of which are fibrosis and cirrhosis.
Objective. To discuss the effects and therapeutic targets of ursodeoxycholic acid drugs in the complex therapy of non-alcoholic fatty liver disease.
Results. The goal of therapeutic measures in non-alcoholic fatty liver disease is to prevent the development of steatosis by acting on modifiable risk factors, and if it is present, prevent the progression of steatosis to non-alcoholic steatohepatitis, liver fibrosis, and reduce the risk of cardiovascular complications. Particular attention is paid to the use of the drug ursodeoxycholic acid.
Conclusion. The experimental and clinical data accumulated to date indicate that ursodeoxycholic acid is a pleiotropic drug, the main effects of which are: a decrease in the severity of insulin resistance and steatosis, lipotoxicity, and normalization of the blood lipid spectrum
About the Author
E. A. Ljaljukova
Federal State Budgetary Educational Institution of Higher Education Omsk State Medical University oof the Ministry of Health of the Russian Federation
Россия
Россия
Elena A. Ljaljukova, Dr. of Sci. (Med.), Professor of the Department of Internal Medicine and Family Medicine
5 Petr Nekrasov str., Omsk, 644037
References
1. Younossi Z. M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver diseaseMeta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73-84.
2. Maev I. V., Andreev D. N., Kucheryavyi Yu. A. The prevalence of non-alcoholic fatty liver disease in Russia: a meta-analysis. ConsiliumMedicum. 2023; 25 (5). DOI: 10.26442/ 20751753.2023.5.202155 (In Russ.)
3. Ivashkin V. T., Maevskaya M. V., Zharkova M. S., Kotovskaya Yu. V., Tkacheva O. N., Troshina Ye. A., Shestakova M.V., Maev I. V., Breder V. V., Geivandova N. I., Doschitsin V. L., Dudinskaya Ye. N., Ershova Ye. V., Kodzoeva Kh. B., Komshilova K. A., Korochanskaya N. V., Maiorov A. Yu., Mishina Ye. Ye., Nadinskaya M. Yu., Nikitin I. G., Pogosova N. V., Tarzimanova A. I., Shamkhalova M. Sh. Clinical guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the Russian Association of Endocrinologists, the Russian Association of Gerontologists and Geriatrics and the National Society of Preventive Cardiology for the diagnosis and treatment of nonalcoholic fatty liver disease. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2022; 32 (4):104-140. https://doi.org/10.22416/1382- 4376-2022-32-4-104-140 (In Russ.)
4. Lazebnik L. B., Golovanova E. V., Turkina S. V., Raikhelson K. L., Okovityi S. V., Drapkina O. M., Maev I. V., Martynov A. I., Roitberg G. E., Khlynova O. V., Abdulganieva D. I., Alekseenko S. A., Ardatskaya M. D., Bakulin I. G., Bakulina N. V., Bueverov A. O., Vinitskaya E. V., Volynets G. V., Eremina E. Yu., Grinevich V. B., Dolgushina A. I., Kazyulin A. N., Kashkina E. I., Kozlova I. V., Konev Yu. V., Korochanskaya N. V., Kravchuk Yu. A., Li E. D., Loranskaya I. D., Makhov V. M., Mekhtiev S. N., Novikova V. P., Ostroumova O. D., Pavlov Ch. S., Radchenko V. G., Samsonov A. A., Sarsenbaeva A. S., Saifutdinov R. G., Seliverstov P. V., Sitkin S. I., Stefanyuk O. V., Tarasova L. V., Tkachenko E. I., Uspenskii Yu. P., Fominykh Yu. A., Havkin A. I., Tsyganova Yu. V., Sharkhun O. O. Non-alcoholic fatty liver disease in adults: clinic, diagnosis, treatment. Recommendations for therapists, third version. Eksperimentalnaya i klinicheskaya gastroenterologiya. 2021; 185 (1): 4-52. DOI: 10.31146/1682-8658-ecg-185-1-4-52 (In Russ.)
5. Jichitu A., Bungau S., Stanescu A. M.A., Vesca C. M., Toma M. M., Bustea C., et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel). 2021; 11 (4): 689. DOI: 10.3390/diagnostics11040689.
6. De Lucia Rolfe E., Brage S., Sleigh A., Finucane F., Griffin S. J., Wareham N. J., Ong K. K., Forouhi N. G. Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults. PLoS One. 2018; 13 (11): e0207923. DOI: 10.1371/ journal.pone.0207923. PMID: 30475885; PMCID: PMC6258232.
7. Kleiner D. E., Makhlouf H. R. Histology of Nonalcoholic Fatty Liver Disease andNonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis. 2016; 20 (2): 293-312. DOI: 10.1016/j. cld.2015.10.011.
8. Eslam M., Sanyal A. J., George J. MAFLD: a consensus driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020 Feb 8. DOI: 10.1053/gastro.2019.11.312.
9. Caviglia G. P., Rosso C., Fagoonee S., Saracco G. M., Pellicano R. Liver fibrosis: The 2017 state of art. Panminerva Med. 2017; 59: 320-331.
10. Stattermayer A. F., Traussnigg S., Dienes H. P., Aigner E., Stauber R., Lackner K., Hofer H., Stift J., Wrba F., Stadlmayr A., et al. Hepatic steatosis in Wilson disease Role of copper and PNPLA3 mutations. J. Hepatol. 2015; 63: 156-163.
11. Gellert-Kristensen H., Richardson T. G., Davey Smith G., Nordestgaard B. G., TybjaergHansen A., Stender S. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology. 2020; 72: 845-856.
12. Kawaguchi T., Shima T., Mizuno M., Mitsumoto Y., Umemura A., Kanbara Y., Tanaka S., Sumida Y., Yasui K., Takahashi M., et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS ONE. 2018; 13: e0185490.
13. Donati B., Dongiovanni P., Romeo S., Meroni M., McCain M., Miele L., Petta S., Maier S., Rosso C., De Luca L., et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci. Rep. 2017; 7: 4492.
14. Gellert-Kristensen H., Nordestgaard B. G., Tybjaerg-Hansen A., Stender S. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant. Hepatology. 2020; 71: 56-66.
15. Murphy S. K., Yang H., Moylan C. A., Pang H., Dellinger A., Abdelmalek M. F., Garrett M. E., Ashley-Koch A., Suzuki A., Tillmann H. L., et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013; 145: 1076-1087.
16. Jonas W., Schurmann A. Genetic and epigenetic factors determining NAFLD risk. Mol. Metab. 2020; 101111.
17. Baker P. R., 2nd, Friedman J. E. Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease. J. Clin. Investig. 2018; 128: 3692-3703.
18. Chalasani N., Younossi Z., Lavine J. E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67: 328-357. https://doi.org/10.1002/hep.29367.
19. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388- 1402. https://doi.org/10.1016/j.jhep.2015.11.004. 27062661. Search in Google ScholarPubMed.
20. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A. J., Natale S., Forlani G., Melchionda N. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes. 2001; 50: 1844-1850.
21. Younossi Z. M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73-84.
22. De Lucia Rolfe E., Brage S., Sleigh A., Finucane F., Griffin S. J., Wareham N. J., Ong K. K., Forouhi N. G. Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults. PLoS One. 2018; 13 (11): e0207923. DOI: 10.1371/journal.pone.0207923. PMID: 30475885; PMCID: PMC6258232.
23. Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33. https://doi.org/10.1186/1471-230X-6-33.
24. Guerra-Ruiz A. R., Casals G., Iruzubieta P., Lalana M., Leis A., López R. M., Crespo J., Morales-Ruiz M. "Biochemical assessment of metabolic associated fatty liver disease" Advances in Laboratory Medicine. Avances en Medicina de Laboratorio. 2021; 2 (2): 199-208. https://doi.org/10.1515/almed-2021-0009.
25. Radu F., Potcovaru C.-G., Salmen T., Filip P. V., Pop C., Fierbinţeanu-Braticievici C. The Link between NAFLD and Metabolic Syndrome. Diagnostics. 2023; 13: 614. https://doi.org/10.3390/diagnostics13040614.
26. Mazloomzadeh S., Karami Zarandi F., Shoghli A., Dinmohammadi H. Metabolic Syndrome, Its Components and Mortality: A Population-Based Study. Med. J. Islam. Repub. Iran. 2019; 33: 11.
27. State register of medicines. https://grls.rosminzdrav.ru/Default.aspx (In Russ.)
28. Kucheryavyi Yu. A., Cheremushkin S. V. Evaluation of the therapeutic efficacy of the reference drug ursodeoxycholic acid and its analogues in the dissolution of biliary sludge: a meta-analysis. ConsiliumMedicum. 2022. № 12. URL: https://cyberleninka.ru/article/n/otsenka-terapevticheskoy-effektivnostireferentnogo-preparata-ursodezoksiholevoykisloty-i-ego-analogov-v-rastvorenii-biliarnogo (Accessed: 08.08.2023). (In Russ.)
29. Kazyulin A. N. The place of ursodeoxycholic acid in the treatment of non-alcoholic fatty liver disease at different stages of the disease: steatosis, steatohepatitis, fibrosis/cirrhosis. RMJ. 2017; 17: 1248-1257. https://www.rmj.ru/articles/gastroenterologiya/Mesto_ursodezoksiholevoy_kisloty_v_terapii_nealkogolynoy_ghirovoy_bolezni_pecheni_na_raznyh_stadiyah_zabolevaniya_steatoz_steatogepatit_fibrozcirroz/#ixzz89OrweUKb (In Russ.)
30. Cukanov V. V., Kasparov Je. V., Tonkih Ju. L., Vasjutin A. V. Novye aspekty nealkogol'noj zhirovoj bolezni pecheni. RZhGGK. 2015; 4: 34-38. (In Russ.) https://www.rmj.ru/articles/gastroenterologiya/Mesto_ursodezoksiholevoy_kisloty_v_terapii_nealkogolynoy_ghirovoy_bolezni_pecheni_na_raznyh_stadiyah_zabolevaniya_steatoz_steatogepatit_fibrozcirroz/#ixzz89OsXmEJT. [Tsukanov V. V., Kasparov E. V., Tonkikh Yu. L., Vasuytin A. V. New aspects of non-alcoholic fatty liver disease. RZhGGK. 2015; 4: 34-38. https://www.rmj.ru/articles/gastroenterologiya/Mesto_ursodezoksiholevoy_kisloty_v_terapii_nealkogolynoy_ghirovoy_bolezni_pecheni_na_raznyh_stadiyah_zabolevaniya_steatoz_steatogepatit_fibrozcirroz/#ixzz89OsXmEJT (in Russ.)]
31. Morozov S. V., Kucheryavyi Yu. A. Hepatoprotectors in clinical practice: rational aspects of use. Manual for doctors. M.: 4TE Art. 2011. 28 phttps://www.rmj.ru/articles/gastroenterologiya/Mesto_ursodezoksiholevoy_kisloty_v_terapii_nealkogolynoy_ghirovoy_bolezni_pecheni_na_raznyh_stadiyah_zabolevaniya_steatoz_steatogepatit_fibrozcirroz/#ixzz89OtA5yOk (in Russ.)
Review
For citations:
Ljaljukova E.A. Non-alcoholic fatty liver disease: a heterogeneous phenotype. Pleiotropic effects of ursodeoxycholic acid. Lechaschi Vrach. 2023;(7-8):19-25. (In Russ.) https://doi.org/10.51793/OS.2023.26.8.003
Views:
169
JATS XML
Email this article 
